BioCentury | Mar 14, 2016
Emerging Company Profile

AMO's CNS ammunition

...Snape declined to compare AMO-01 to other clinical candidates, but cited Neuren Pharmaceuticals Ltd .'s trofinetide...
BioCentury | Dec 8, 2014
Clinical News

NNZ-2566: Phase II data

...NNZ-2566 for up to 28 days were well tolerated with no safety concerns identified. High-dose NNZ-2566...
...of Motor Behavior Assessment Change Index, CGI-I and Caregiver Top 3 Concerns scores. Additionally, high-dose NNZ-2566...
...score and Modified Apnea Index scores. Neuren said that the magnitude of improvement with low-dose NNZ-2566...
BioCentury | Sep 15, 2008
Company News

Neuren, U.S. Army neurology news

...a $5.5 million grant from the U.S. Army to fund a Phase II trial of NNZ-2566...
BioCentury | Dec 10, 2007
Clinical News

NNZ-2566: Phase IIa start

...single bolus injection of 20 mg/kg NNZ-2566 followed by an IV infusion of 6 mg/kg/hour NNZ-2566...
...more robust dataset (see BioCentury, May 14). Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
BioCentury | Dec 10, 2007
Clinical News

NNZ-2566: Phase II start

...evaluate a 20 mg/kg bolus of NNZ-2566 followed by a 6 mg/kg/hour IV infusion of NNZ-2566...
...more robust dataset (see BioCentury, May 14). Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
BioCentury | Nov 12, 2007
Clinical News

NNZ-2566: Phase Ib data

...Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566 Business: Inflammation Molecular target: Not available Description...
...data Milestone: Start Phase II (mid-2008) In an Australian Phase Ib trial in 28 volunteers, NNZ-2566...
...tolerated at all 4 dose levels. All patients received a 10-minute infusion of 20 mg/kg NNZ-2566...
BioCentury | May 14, 2007
Clinical News

NNZ-2566: Phase IIa start

...U.S. Phase IIa trial in 40-50 patients. Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
BioCentury | May 14, 2007
Clinical News

NNZ-2566: Phase IIb start

...Phase IIb trial in about 200 patients. Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
BioCentury | May 14, 2007
Clinical News

NNZ-2566: Phase II start

...Australian and New Zealand Phase II trial in 60-70 patients to evaluate a bolus of NNZ-2566...
...by an IV infusion for 12-24 hours. Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
BioCentury | Jan 22, 2007
Clinical News

NNZ-2566: Phase I data

...In a dose-escalation, Australian Phase I trial in 28 healthy volunteers, NNZ-2566 was safe at the...
...longer infusions of 12 or 24 hours. Neuren Pharmaceuticals Ltd. (ASX:NEU), Auckland, New Zealand Product: NNZ-2566...
Items per page:
1 - 10 of 15